Erratum: Association of fibrosis with mortaliy and sudden cardiac death in patients with nonischemic dilated cardiomyopathy (JAMA - Journal of the American Medical Association (2013) 309, 9 (896-908) DOI:10.1001/jama.2013.1363);Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy

JAMA

Volumn 309, Issue 9, 2013, Pages 896-908

  Gulati, Ankur ^e   Jabbour, Andrew ^e   Ismail, Tevfik F ^a,b   Guha, Kaushik ^a,b   Khwaja, Jahanzaib ^e   Raza, Sadaf ^e   Morarji, Kishen ^e   Brown, Tristan D H ^e   Ismail, Nizar A ^e   Dweck, Marc R ^c   Di Pietro, Elisa ^e   Roughton, Michael ^e   Wage, Ricardo ^e   Daryani, Yousef ^e   O'Hanlon, Rory ^e   Sheppard, Mary N ^a,b   Alpendurada, Francisco ^e   Lyon, Alexander R ^a,b   Cook, Stuart A ^a,b,d   Cowie, Martin R ^a,b   Assomull, Ravi G ^e   Pennell, Dudley J ^a,b   Prasad, Sanjay K ^a,b   more..

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d DEPARTMENT OF CARDIOLOGY   (Singapore)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

GADOBUTROL; GADOLINIUM PENTETATE MEGLUMINE; DIAGNOSTIC AGENT; GADOLINIUM;

ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CONGESTIVE CARDIOMYOPATHY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HUMAN; LATE GADOLINIUM ENHANCEMENT CARDIOVASCULAR MAGNETIC RESONANCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONISCHEMIC DILATED CARDIOMYOPATHY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SUDDEN DEATH; AGED; CAUSE OF DEATH; FIBROSIS; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART STROKE VOLUME; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; UNITED KINGDOM;

ADULT; AGED; CARDIOMYOPATHY, DILATED; CAUSE OF DEATH; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; FIBROSIS; GADOLINIUM; GREAT BRITAIN; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

MLCS; MLOWN;

EID: 84874719002     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.7393     Document Type: Erratum

References (45)

1. Jefferies JL, Towbin JA. Dilated cardiomyopathy. Lancet. 2010;375(9716):752-762.
2. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077-1084.
3. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391-e479.
4. Rihal CS, Nishimura RA, Hatle LK, Bailey KR, Tajik AJ. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy. Relation to symptoms and prognosis. Circulation. 1994;90(6):2772-2779.
5. Grzybowski J, Bilińska ZT, Ruzyłło W, et al. Determinants of prognosis in nonischemic dilated cardiomyopathy. J Card Fail. 1996;2(2):77-85.
6. Goldberger JJ, Cain ME, Hohnloser SH, et al American Heart Association; American College of Cardiology Foundation; Heart Rhythm Society. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. Circulation. 2008;118(14):1497-1518.
7. Goldberger JJ, Buxton AE, Cain M, et al. Risk stratification for arrhythmic sudden cardiac death: identifying the roadblocks. Circulation. 2011;123(21):2423-2430.
8. Stecker EC, Chugh SS. Prediction of sudden cardiac death: next steps in pursuit of effective methodology. J Interv Card Electrophysiol. 2011;31(2):101-107.
9. Baig MK, Mahon N, McKenna WJ, et al. The pathophysiology of advanced heart failure. Am Heart J. 1998;135(6 Pt 2):S216-S230.
10. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005;111(21):2837-2849.
11. Hsia HH, Marchlinski FE. Electrophysiology studies in patientswith dilated cardiomyopathies. Card Electrophysiol Rev. 2002;6(4):472-481.
12. Iles L, Pfluger H, Lefkovits L, et al. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter- defibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol. 2011;57(7):821-828.
13. McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003;108(1):54-59.
14. Pennell DJ. Cardiovascular magnetic resonance. Circulation. 2010;121(5):692-705.
15. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J. 2005;26(15):1461-1474.
16. Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48(10):1977-1985.
17. Wu KC, Weiss RG, Thiemann DR, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51(25):2414-2421.
18. Lehrke S, Lossnitzer D, Schöb M, et al. Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Heart. 2011;97(9):727-732.
19. Leyva F, Taylor RJ, Foley PW, et al. Left ventricular midwall fibrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. J Am Coll Cardiol. 2012;60(17):1659-1667.
20. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996;93(5):841-842.
21. Maceira AM, Prasad SK, Khan M, Pennell DJ. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2006;8(3):417-426.
22. Hundley WG, Bluemke DA, Finn JP, et al American College of Cardiology Foundation Task Force on Expert Consensus Documents. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010;121(22):2462-2508.
23. O'Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56(11):867-874.
24. Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML; MADIT-II Investigators. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol. 2004;43(8):1459-1465.
25. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. 2008;27(2):157-172 Stat Med.
26. UK Department of Health. Sensible drinking: the report of an inter-departmental working group. http://www.dh.gov.uk/prod-consum-dh/groups/dh- digitalassets/@dh/@en/documents/digitalasset/dh-4084702.pdf. Accessibility verified February 4, 2013.
27. de Leeuw N, Ruiter DJ, Balk AH, de Jonge N, Melchers WJ, Galama JM. Histopathologic findings in explanted heart tissue from patients with end-stage idiopathic dilated cardiomyopathy. Transpl Int. 2001;14(5):299-306.
28. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med. 1994;331(23):1564-1575.
29. Aleksova A, Sabbadini G, Merlo M, et al. Natural history of dilated cardiomyopathy: from asymptomatic left ventricular dysfunction to heart failure - a subgroup analysis from the Trieste Cardiomyopathy Registry. J Cardiovasc Med (Hagerstown). 2009;10(9):699-705.
30. Cygankiewicz I, Zareba W, Vazquez R, et al MUSIC Investigators. Risk stratification of mortality in patients with heart failure and left ventricular ejection fraction >35%. Am J Cardiol. 2009;103(7):1003-1010.
31. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292(23):2874-2879.
32. Bardy GH, Lee KL, Mark DB, et al Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-237.
33. Cleland JG, Daubert JC, Erdmann E, et al Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539- 1549.
34. Dickstein K, Cohen-Solal A, Filippatos G, et al ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology: developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) [published correction appears in Eur Heart J. 2010;12(4):416]. Eur Heart J. 2008;29(19):2388-2442.
35. Epstein AE, Dimarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2013;127(3):e283-e352.
36. Ezekowitz JA, Rowe BH, Dryden DM, et al. Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med. 2007;147(4):251-262.
37. Zipes DP, Camm AJ, Borggrefe M, et al European Heart Rhythm Association; Heart Rhythm Society; American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol. 2006;48(5):e247- e346.
38. Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359(10):1009-1017.
39. Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol. 2008;52(14):1111-1121.
40. Mishkin JD, Saxonhouse SJ, Woo GW, et al. Appropriate evaluation and treatment of heart failure patients after implantable cardioverter-defibrillator discharge: time to go beyond the initial shock. J Am Coll Cardiol. 2009;54(22):1993-2000.
41. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353(14):1471-1480.
42. Grimm W, Christ M, Bach J, Müller HH, Maisch B. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation. 2003;108(23):2883-2891.
43. Aleksova A, Barbati G, Merlo M, et al. Deleterious impact of mild anemia on survival of young adult patients (age 45 ± 14 years) with idiopathic dilated cardiomyopathy: data from the Trieste Cardiomyopathies Registry. Heart Lung. 2011;40(5):454-461.
44. Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57(8):891-903.
45. White SK, Sado DM, Flett AS, Moon JC. Characterising the myocardial interstitial space: the clinical relevance of non-invasive imaging. Heart. 2012;98(10):773-779.